Market News
Smart Trading. Simplified.
Jeff Bezos, Goldman Sachs and a Big Pharma giant have invested billions into this stock.
On August 23, 2018, this small biotech won a patent for a treatment that could help as many as 50 million people...and save the U.S. as much as $20 TRILLION. Jim Cramer says a drug like this would be "The Biggest Drug Ever." And our research shows that anyone who gets in today could turn every $1,000 into $1.1 million.
Winklevoss Twins Bitcoin Prediction
Most people know the Winklevoss Twins (Cameron and Tyler) as students who attended Harvard with Mark Zuckerberg. The two created a social media platform called ConnectU that, according to a lawsuit, Zuckerberg stole to create Facebook. More recently, the Winklevoss Twins have been involved in cryptocurrency. Their expertise in the industry means that people pay […]
Tired of losing money in volatile markets?
Enter the "Vomma Zone." A unique market environment discovered by former TD Ameritrade educator Don Kaufman that makes massive profits available to every trader.
Don has a special member-only video briefing that teaches traders how to thrive in extreme volatility.
Learn the ins, outs, tricks, and tips expert traders use daily to spot this unique moment in the market.
5 Top Stocks For Post Covid
While the stock market rebounded well after the initial Covid-19 shock, certain industries and companies suffered. Most businesses that cannot operate remotely or provide unessential services struggled to earn revenues. As a result, their stock prices fell – and many have not recovered. As more people get vaccinated against the virus, you can expect people […]
Is this Killer new EXTRA INCOME strategy the Best Side Hustle EVER?
Have you seen this new extra-income hack yet?
Everyday Americans have been making 100%, 200%, 500%, or more... sometimes in a matter of days with this one new strategy. Some of them are retiring from their jobs because of it. Others have paid off all their debt and bought their dream homes.
You can see their stories for yourself right here.
Will Ethereum Hit 20k?
Will Ethereum Hit 20k? By many measures, Bitcoin has gone mainstream. Anyone can trade it through well-known brokerage apps like Robinhood, and significant organizations such as Tesla (TSLA) and Square (SQ) have elected to substitute Bitcoin for a portion of the cash on their balance sheets. Bitcoin is just one of 4,000 unique cryptocurrencies, and […]
Profit-Stocks: Upstart Gold Firm Hits High-Grade Gold Zone
In the gold sector, it's the tiny, low-priced exploration firms that typically make the initial discovery through drilling. It's also where investors can secure 10-fold and even 20-fold gains as early drill results are released to the public. Investors are currently jumping into this low-priced gold driller that just hit a high-grade discovery hole in Canada with additional results due any day.
5 Bargain Stocks To Buy Now
Stamps.com Growth Is Impressive Despite what was undoubtedly a stellar fiscal 2020 for Stamps.com, its share price suffered a major downturn. Dropping 36% from February highs of $274 to a low of $170 in March this year, its current value has stabilized to around the $205 level. And even with the positive news of revenue […]
The World's First $2 Trillion Drug?
The Wall Street Journal reports new treatment is "transforming medicine."
Bill Gates writes that it could "help humanity."
Ark Investments think it could be a "$2 trillion market."
And one small company owns the patent on it.
This unknown biotech's stock is set to surge 46,751% >>>
Why Is Cathie Wood Famous?
Why Is Cathie Wood Famous? Given the nature of the stock market, it’s not uncommon to see many prominent names come and go quite quickly as time goes on and the market changes. However, over the past several years, there’s been one name that seems to be thrown around more, not less. That name is […]
Climb aboard 2021's most exciting investment trend.
As a strong supply-demand story drives the spot price of uranium up 24.15% between Jan. and April 2021, one soaring company offers an attractive entry into the market.
View this email online if it doesn't display correctly. This newsletter is not financial advice. Please read our Disclaimer.
To unsubscribe from Financhill, click here.
Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.
The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity's compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.
The content on any of Financhill websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The Financhill.com educational training program and software services are provided to improve financial understanding.
The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.
Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.
No comments:
Post a Comment